Zanubrutinib Faces Off Against Ibrutinib in CLL Trial

Rachel Narozniak, MA
Published: Wednesday, Jan 08, 2020
Dr Jennifer R. Brown

Jennifer R. Brown, MD, PhD

Armed with the knowledge that inhibition of the Bruton tyrosine kinase (BTK) is an effective approach in B-cell malignancies, investigators will explore the efficacy of the second-generation BTK inhibitor, zanubrutinib (Brukinsa), in 2 leukemia and lymphoma subtypes.1

Figure. Zanubrutinib Evaluated in CLL, SLL (Click to Enlarge)

Patients with RR CLL and SLL will be randomized to receive either singleagent zanubrutinib at 160 mg twice daily or ibrutinib monotherapy at 420 mg once daily. The primary end point is overall response rate (ORR) determined by independent central review. Secondary end points include AEs, duration of response, overall survival, progression-free survival (PFS), patient-reported outcomes, and time to treatment failure (Figure).

Investigators will stratify patients by age (<65 years vs ≥65 years), refractory status, geographic region, and the presence or absence of deletion in chromosome 17p [del(17p)] or TP53 mutations.1 In CLL, del(17p) and TP53 are 2 of the strongest predictive markers of treatment response.5

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication